(1 - 9 from 13
)
Pergamum reports positive Phase II data from clinical trial
www.globenewswire.com
STOCKHOLM – December 21, Pergamum AB announced today that the primary end -point was met in the randomized Phase II trial of DPK-060 for treatment of...
Jonas Ekblom appointed new Pergamum CEO
www.wallstreet-online.de
STOCKHOLM - October 28, Jonas Ekblom has been appointed as new Chief
Executive Officer of Pergamum AB, the dermatology and wound healing...
Pergamum reports positive follow-up data from a Phase II
www.globenewswire.com
STOCKHOLM – June 27, Pergamum AB announced today that several end-points were met in a randomized Phase II trial of PXL-01 for prevention of post...
sorted by relevance / date